drugset / Trial / NCT06405100
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
Phase 3
Not yet recruiting
81 enrolled
Air Force Military Medical University, China
First Affiliated Hospital Xi'an Jiaotong University · collabSecond Affiliated Hospital of Xi'an Jiaotong University · collabShaanxi Provincial Hospital of Chinese Medicine · collabShaanxi Provincial People's Hospital · collabThe Second Affiliated Hospital of Air Force Military Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.
Timeline
- Start
- 2024-05
- Primary completion
- 2026-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prednisone | Other / unclassified | 5 mg | — |
| Comparator | Tacrolimus | Small molecule | 0.05 mg/kg | — |
| Comparator | ripertamab | Monoclonal antibody | 1000 mg | — |